学术研究-上海孟超肿瘤医院

Fang, J., et al. (2021). "alphaPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib." J Immunother Cancer 9(2).

2

Fang, Y., et al. (2020). "Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells." Mol Ther Methods Clin Dev 19: 14-23.

3

Han, D., et al. (2021). "Current Progress in CAR-T Cell Therapy for Hematological Malignancies." J Cancer 12(2): 326-334.

4

Qiu, J., et al. (2020). "Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients." Cancer Manag Res 12: 209-219.

5

Zhang, Y., et al. (2021). "Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy." J Transl Med 19(1): 82.

6

Zhang, Y., et al. (2021). "Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients." J Cancer Res Clin Oncol.